Antibiotics and the lung: pharmacokinetic and pharmacodynamic issues Source: Annual Congress 2004 - PG22 - New perspectives in pneumonia treatment and prophylaxis Year: 2004
Pharmacokinetics and pharmacodynamics of newer fluoroquinolones in patients with lower respiratory tract infections Source: Annual Congress 2012 - Management of severe respiratory infections Year: 2012
Pharmacological interactions between antibiotics and other drugs in the treatment of lower respiratory tract infections Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=229 Year: 2004
Population pharmacokinetics and pharmacodynamics analysis of vancomycin in patients with severe lower respiratory tract gram-positive infections Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014
Population pharmacokinetics and pharmacodynamics of meropenem in elderly Chinese with lower respiratory tract infection Source: Annual Congress 2010 - Treatment and risk factors in lower respiratory tract infections Year: 2010
Interrelationship of pharmacokinetics/pharmacodynamics: antibiotic dosing for the future Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=1 Year: 2004
Efficacy and safety of Cefdinir in lower respiratory tract infections Source: Eur Respir J 2002; 20: Suppl. 38, 420s Year: 2002
Immunomodulatory effects of moxifloxacin in human respiratory tract infection Source: Annual Congress 2010 - Treatment and risk factors in lower respiratory tract infections Year: 2010
Mechanistic model based meta-analysis for paediatric respiratory tract infection prophylaxis trial design Source: Virtual Congress 2021 – Paediatric respiratory infections: chronic infection, vaccination and lung function Year: 2021
Nontuberculosis mycobacteria infections: would there be pharmacodynamics without pharmacokinetics? Source: Eur Respir J, 54 (5) 1901508; 10.1183/13993003.01508-2019 Year: 2019
Nontuberculosis mycobacteria infections: would there be pharmacodynamics without pharmacokinetics? Source: Eur Respir J, 54 (5) 1901806; 10.1183/13993003.01806-2019 Year: 2019
Pharmacodynamic and pharmacokinetic results after repeated doses of AZD8871 in COPD patients Source: International Congress 2018 – Clinical trials in COPD: new results Year: 2018
Empiric antibiotic treatment and pathogens resistance in respiratory tract infections; a prospective epidemiological survey Source: Eur Respir J 2003; 22: Suppl. 45, 335s Year: 2003
Streptococcal resistance to antibiotics in children with upper respiratory tract infections. Epidemiological aspects Source: Annual Congress 2010 - Paediatric respiratory infection, inflammation and immunology Year: 2010
Bacterial agents of community-acquired lower respiratory tract infections: observational study on antimicrobial drugs susceptibility Source: Eur Respir J 2002; 20: Suppl. 38, 421s Year: 2002
Potential impact and relevance of diagnostics in the management of respiratory tract infections: from COVID to hospital-acquired pneumonia Source: Virtual Congress 2021 – Emerging data for the management of respiratory tract infections Year: 2021
Intrapulmonary penetration of antimicrobials and implications in the treatment of lower respiratory tract infections Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=13 Year: 2004
Development and validation of high performance computing simulation of respiratory tract of inhaled drug and pharmacokinetics Source: Eur Respir J 2004; 24: Suppl. 48, 581s Year: 2004
Simultaneous use of probiotics and vaccines for prevention of pneumonia and respiratory infections in servicemen Source: Eur Respir J 2006; 28: Suppl. 50, 154s Year: 2006